Dexcom, Inc., Data Science, San Diego, California, USA.
Dexcom, Inc., Global Clinical Initiatives, San Diego, California, USA.
Diabetes Technol Ther. 2021 Jul;23(7):508-511. doi: 10.1089/dia.2021.0014. Epub 2021 Mar 5.
We aimed to describe patterns of continuous glucose monitoring (CGM) system use and glycemic outcomes from 2018 to 2020 in a large real-world cohort by analyzing anonymized data from US-based CGM users who transitioned from the G5 to the G6 System (Dexcom) in 2018. The main end points were persistent use, within-day and between-day utilization, hypoglycemia, time in range (TIR, 70-180 mg/dL [3.9-10 mmol/L]), and use of the optional calibration feature in 2019 and 2020. In a cohort of 31,034 individuals, rates of persistent use were high, with 27,932 (90.0%) and 26,861 (86.6%) continuing to upload data in 2019 and 2020, respectively. Compared with G5 use, G6 use was associated with higher device utilization, less hypoglycemia, higher TIR (in 2020), and >80% fewer calibrations in both 2019 and 2020 (s < 0.001). High persistence and utilization of the G6 system may contribute to sustainable glycemic outcomes and decreased user burden.
我们旨在通过分析 2018 年从 G5 系统过渡到 G6 系统(德康)的美国 CGM 用户的匿名数据,描述 2018 年至 2020 年连续血糖监测(CGM)系统使用模式和血糖结果在大型真实队列中的变化。主要终点是在 2019 年和 2020 年持续使用、日内和日间利用、低血糖、达标时间(TIR,70-180mg/dL [3.9-10mmol/L])和可选校准功能的使用情况。在 31034 名个体的队列中,持续使用率较高,分别有 27932(90.0%)和 26861(86.6%)在 2019 年和 2020 年继续上传数据。与 G5 相比,G6 使用与更高的设备利用率、更少的低血糖、更高的 TIR(在 2020 年)以及在 2019 年和 2020 年减少超过 80%的校准次数相关(s<0.001)。G6 系统的高持续性和利用率可能有助于实现可持续的血糖控制结果并降低用户负担。